Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data

Current Medical Research and Opinion
Vijayveer BonthapallyDirk Huebner

Abstract

This meta-analysis evaluated the antitumor activity of brentuximab vedotin versus historical values in patients with relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplantation (ASCT). A systematic literature review identified studies (1993-February 2013) reporting complete remission (CR) rates in patients with relapsed/refractory Hodgkin lymphoma post-ASCT. Publications reporting CR rates, identified through interrogation of multiple electronic databases and manual searches (with search terms used to capture 'relapsed', 'refractory', 'HL', and 'ASCT'), were included if they reported: ≥20 relapsed/refractory Hodgkin lymphoma patients, where ≥80% were aged ≥12 years and ≥50% had failed prior ASCT. Overall CR rate was determined using a random-effect model, and compared with that reported for brentuximab vedotin in a pivotal phase 2 trial (SG035-0003). Across 17 evaluable studies of historical or experimental agents (n = 812), the estimated overall CR rate was 11.1% (95% confidence interval [CI] 7.0, 17.6; range, 0-38.5%) versus 33.3% (95% CI 25.3, 43.9) for brentuximab vedotin (p < 0.0001). In sensitivity analyses, the estimated overall CR rates for historical/experimental agents were 13.6% (95% CI 8.7, 21.4) ...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
Jun 5, 2003·Nature Biotechnology·Svetlana O DoroninaPeter D Senter
Mar 2, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SuredaUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland SchnellAndreas Engert
Apr 28, 2006·The New England Journal of Medicine·Edward A Copelan
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Apr 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L BartlettUNKNOWN Cancer Leukemia Group B
May 23, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen M AnsellPeter Borchmann
Jun 17, 2008·The Oncologist·Richard Pazdur
May 27, 2009·British Journal of Haematology·Andres Forero-TorresAjay K Gopal
Jan 21, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicole M OkeleyStephen C Alley
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Panayotis KaloyannidisAchilles Anagnostopoulos
Sep 16, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeUNKNOWN NCCN Hodgkin Lymphoma
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesAndreas Engert
May 10, 2012·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeUNKNOWN National Comprehensive Cancer Network
Jun 13, 2012·Nature Reviews. Clinical Oncology·Peter BorchmannAndreas Engert
Nov 22, 2012·British Journal of Haematology·Gaetano CorazzelliAntonio Pinto
Dec 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison J MoskowitzCraig H Moskowitz
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Aug 15, 2013·Current Opinion in Oncology·Bastian von Tresckow, Andreas Engert

❮ Previous
Next ❯

Citations

Dec 15, 2015·Expert Opinion on Drug Delivery·Sagun ParakhAndrew M Scott
Apr 21, 2016·Expert Opinion on Biological Therapy·R DadaRawan Al Saadi
May 29, 2018·La Revue de médecine interne·C Rossi, J N Bastie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.